TCIM
RARE icon

TIAA CREF Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

TIAA CREF Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$9.46M Buy
136,413
+5,619
+4% +$321K 0.01% 1066
2018
Q4 		$5.69M Sell
130,794
-15,116
-10% -$826K ﹤0.01% 1291
2018
Q3 		$11.1M Sell
145,910
-37,288
-20% -$3.03M 0.01% 1050
2018
Q2 		$14.1M Sell
183,198
-12,661
-6% -$818K 0.01% 943
2018
Q1 		$9.99M Buy
195,859
+55,921
+40% +$2.82M 0.01% 1116
2017
Q4 		$6.49M Buy
139,938
+23,589
+20% +$1.16M ﹤0.01% 1446
2017
Q3 		$6.2M Sell
116,349
-2,354
-2% -$139K ﹤0.01% 1484
2017
Q2 		$7.37M Sell
118,703
-18,170
-13% -$1.09M 0.01% 1326
2017
Q1 		$9.28M Sell
136,873
-6,858
-5% -$523K 0.01% 1166
2016
Q4 		$10.1M Sell
143,731
-6,313
-4% -$448K 0.01% 1112
2016
Q3 		$10.6K Sell
150,044
-2,621
-2% -$167K 0.01% 1083
2016
Q2 		$7.47M Sell
152,665
-5,468
-3% -$354K 0.01% 1254
2016
Q1 		$10M Sell
158,133
-919
-0.6% -$60.1K 0.01% 1055
2015
Q4 		$17.8M Buy
159,052
+432
+0.3% +$43.2K 0.01% 797
2015
Q3 		$15.3M Buy
158,620
+86,154
+119% +$9.86M 0.01% 841
2015
Q2 		$7.42M Buy
72,466
+38,411
+113% +$2.98M 0.01% 1373
2015
Q1 		$2.11M Hold
34,055
– – ﹤0.01% 2186
2014
Q4 		$1.49M Buy
34,055
+699
+2% +$32K ﹤0.01% 2431
2014
Q3 		$1.89M Buy
33,356
+7,654
+30% +$385K ﹤0.01% 2255
2014
Q2 		$1.15M Buy
25,702
+1,505
+6% +$62K ﹤0.01% 2637
2014
Q1 		$1.18M Buy
+24,197
New +$1.25M ﹤0.01% 2549

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

TIAA CREF Investment Management's RARE Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Ultragenyx Pharmaceutical (RARE) stake by 4.3% in Q1 2019, buying an estimated $321K and bringing the position to 136,413 shares worth $9.46M. The position accounts for 0.01% of the portfolio, ranked #1066.

TIAA CREF Investment Management first reported a position in RARE in Q1 2014 and has held it in 21 quarters since. The position peaked at $17.8M in Q4 2015. 176 funds tracked by Wall St. Rank hold RARE as of Q1 2019.

  • TIAA CREF Investment Management held 136,413 shares of Ultragenyx Pharmaceutical worth $9.46M as of Q1 2019.
  • TIAA CREF Investment Management bought 5,619 Ultragenyx Pharmaceutical shares in Q1 2019, an estimated $321K.
  • Ultragenyx Pharmaceutical made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1066 holding.
  • TIAA CREF Investment Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 21 quarters since.
  • TIAA CREF Investment Management's Ultragenyx Pharmaceutical position peaked at $17.8M in Q4 2015.
  • 176 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.